Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05383196 · ClinicalTrials.gov registry record · Phase 1

Onvansertib + Paclitaxel In TNBC

A Phase 1 study of Breast Cancer and Metastatic Breast Cancer, sponsored by Antonio Giordano, MD.

Active
Registry status
Phase 1
Development phase
50
Enrollment target
3
Study locations

NCT05383196 is a Phase 1 study of Breast Cancer and Metastatic Breast Cancer that is active but no longer recruiting, run by Antonio Giordano, MD. The registered enrollment target is 50 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05383196, a Phase 1 study of Breast Cancer and Metastatic Breast Cancer, is active but no longer recruiting, sponsored by Antonio Giordano, MD.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
50 participants
Enrollment target
3
Study locations

Study Summary

This research is being done to evaluate the safety and effectiveness of Onvansertib in combination with Paclitaxel in triple-negative breast cancer (TNBC) that has spread to other parts of the body. The names of the study interventions involved in this study are: * Onvansertib * Paclitaxel

Conditions Studied

Breast Cancer Metastatic Breast Cancer HER2-Negative Breast Cancer Invasive Breast Cancer Triple Negative Breast Cancer (TNBC) Locally Advanced Breast Cancer Unresectable Breast Carcinoma Inflammatory Breast Cancer Hormone Receptor-Negative Breast Carcinoma Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer

Interventions

  • DRUG Paclitaxel
  • DRUG Onvansertib

Study Locations (3)

Massachusetts

  • Massachusetts General Hospital - Boston
  • Beth Israel Deaconness Medical Center - Boston
  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2022-09-30
Est. Completion 2029-02-15
Phase Phase 1

Sponsor

Antonio Giordano, MD

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05383196

The ClinicalTrials.gov registry entry for NCT05383196 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Antonio Giordano, MD, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Paclitaxel is the first listed.

NCT05383196 reports 3 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05383196 about?

NCT05383196 is a clinical study titled "Onvansertib + Paclitaxel In TNBC". This research is being done to evaluate the safety and effectiveness of Onvansertib in combination with Paclitaxel in triple-negative breast cancer (TNBC) that has spread to other parts of the body. The names of the study interventions involved in this study are: * Onvansertib * Paclitaxel

What is the current status of trial NCT05383196?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2022-09-30. Estimated completion is 2029-02-15.

What conditions does trial NCT05383196 study?

This clinical trial studies the following conditions: Breast Cancer, Metastatic Breast Cancer, HER2-Negative Breast Cancer, Invasive Breast Cancer, Triple Negative Breast Cancer (TNBC).

What interventions are being tested in trial NCT05383196?

The interventions under investigation include: Paclitaxel (DRUG), Onvansertib (DRUG).

Who is sponsoring clinical trial NCT05383196?

This trial is sponsored by Antonio Giordano, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05383196 being conducted?

This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Metastatic Breast Cancer

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.